Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions ...
Jun 3, 2022
0
2
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than ...
Jun 2, 2022
0
1
Around 48,500 people are diagnosed with lung cancer in the UK each year. New treatments are desperately needed as fewer than 20% of patients survive for five years after diagnosis, and it is the biggest cause of death from ...
May 30, 2022
0
388
A new study from McGill University finds higher incidence of lung cancer and brain tumors in people exposed to wildfires. The study, which tracks over 2 million Canadians over a period of 20 years, is the first to examine ...
May 9, 2022
0
439
Over time, cancer cells can evolve to become resistant to treatment, more aggressive, and metastatic—capable of spreading to additional sites in the body and forming new tumors. The more of these traits that a cancer evolves, ...
May 5, 2022
0
89
About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make ...
Apr 28, 2022
0
34
Cancer researchers at Case Western Reserve University School of Medicine say they have successfully suppressed the growth of some solid tumors in research models by manipulating immune cells known as macrophages.
Apr 20, 2022
0
101
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Apr 11, 2022
0
2
Non-small cell lung cancer (NSCLC) is a devastating disease and the leading cause of American cancer deaths. Even patients suitable for tumor removal have a 50% mortality rate. But University of Missouri School of Medicine ...
Apr 6, 2022
0
35
Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them. The findings, ...
Mar 24, 2022
0
76
